Lv51
1000 积分 2021-06-22 加入
High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database
10天前
已完结
A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system
10天前
已完结
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China
19天前
已完结
Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer
1个月前
已完结
Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer
1个月前
已完结
Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial
3个月前
已完结
PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer
3个月前
已完结
Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer
3个月前
已关闭
Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancer
3个月前
已关闭
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
3个月前
已完结
皖公网安备34019202002308
